Vertex Pharmaceuticals Inc. is acquiring Alpine Immune Sciences Inc. for $4.9 billion in cash to gain Alpine’s lead product, phase III-ready povetacicept, which demonstrates best-in-class potential in patients with immunoglobulin A nephropathy (IgAN).
Interest rate-sensitive megacaps gave the tech-heavy Nasdaq a decisive edge. The S&P 500 also closed in positive territory, while the Dow ended essentially unchanged.
Jumps for Big Tech stocks helped U.S. stock indexes claw back much of their slide from the day before, when worries that interest rates may stay high for a while
Stocks that traded heavily or had substantial price changes on Thursday: Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise By The Associated Press…